Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of recombinant human hyaluronidase and regular human insulin. Hyaluronidase is an enzyme that depolymerizes hyaluronic acid in the extracellular matrix, thereby increasing tissue permeability and facilitating the absorption and dispersion of co-administered drugs. When combined with regular human insulin, hyaluronidase accelerates the absorption and onset of action of insulin after subcutaneous injection. This results in faster peak insulin levels, earlier onset, shorter duration of action, and reduced variability in glucose-lowering effects compared to regular insulin alone. The combination has been studied for use in diabetes management to improve postprandial glycemic control by mimicking more physiologic rapid-acting profiles[1][2][3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hyaluronidase + regular human insulin.